How much revenue does Honz Pharmaceutical make?

Honz Pharmaceutical reported 466.12 million CNY in revenue for fiscal year 2025, down 1.4% from 472.82 million CNY in fiscal year 2024. In Q1 2026 revenue was 96.57 million CNY.

What is Honz Pharmaceutical's largest business segment?

Pharmaceutical Manufacturing and Sales Division, with 426.23 million CNY or 90% of segment revenue in fiscal year 2024. Next: Production and Sales of Daily Necessities (10%).

Where does Honz Pharmaceutical make most of its revenue?

China: 100% of revenue by region in fiscal year 2024, followed by Foreign (under 1%).

What companies are similar to Honz Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ), Shanghai Fudan Forward S&T Co., Ltd (600624.SS), Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ), ShanXi C&Y Pharmaceutical Group Co.,LTD. (300254.SZ).

Honz Pharmaceutical Co., Ltd. (300086.SZ) Stock

About Honz Pharmaceutical Co., Ltd.

Honz Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pediatric medicines in China and internationally. It operates through Pharmaceutical Manufacturing and Sales; and Daily Necessities Manufacturing and Sales segments. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal, cough r...

At a glance

Honz Pharmaceutical reported revenue of 466.12 million CNY for fiscal year 2025, down 1.4% from fiscal year 2024, and net income of -230.14 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 96.57 million CNY, down 14.1% from a year before. Its largest business segment, Pharmaceutical Manufacturing and Sales Division, brought in 90% of segment revenue in fiscal year 2024; China was the largest region with 100%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.